Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer
Abstract Background Studying the intracellular distribution of pharmacological agents, including anticancer compounds, is of central importance in biomedical research. It constitutes a prerequisite for a better understanding of the molecular mechanisms underlying drug action and resistance developme...
Main Authors: | Bernhard Englinger, Sebastian Kallus, Julia Senkiv, Daniela Heilos, Lisa Gabler, Sushilla van Schoonhoven, Alessio Terenzi, Patrick Moser, Christine Pirker, Gerald Timelthaler, Walter Jäger, Christian R. Kowol, Petra Heffeter, Michael Grusch, Walter Berger |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-09-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13046-017-0592-3 |
Similar Items
-
Lysosomal Sequestration Impairs the Activity of the Preclinical FGFR Inhibitor PD173074
by: Bernhard Englinger, et al.
Published: (2018-12-01) -
Focus on Nintedanib in NSCLC and other tumors
by: Anna Manzo, et al.
Published: (2016-12-01) -
Profile of nintedanib in the treatment of solid tumors: the evidence to date
by: Awasthi N, et al.
Published: (2015-12-01) -
Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity
by: Seidai Sato, et al.
Published: (2017-09-01) -
The Effect of Nintedanib on T-Cell Activation, Subsets and Functions
by: Ubieta K, et al.
Published: (2021-03-01)